At last week’s American Chemical Society Spring meeting, Bristol Myers Squibb Co. discussed the development of a potent, orally bioavailable and highly selective cereblon (CRBN)-mediated ...

Click here to read the article now. PD-L1 biomarker testing guides cancer treatment decisions. These results are difficult to access because laboratory reports are unstructured and require ...